Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Randomised, Dose-finding Study to Compare the Efficacy (in Terms of Clearance of RhD-positive RBCs) and Safety of LFB-R593, a Monoclonal Anti-RhD Antibody vs a Polyclonal Anti-RhD Immunoglobulin in Healthy RhD Negative Volunteers

NCT00952575 is registered in ClinicalTrials.gov with Laboratoire français de Fractionnement et de Biotechnologies as lead sponsor.

NCT NCT00952575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00952575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Randomised, Dose-finding Study to Compare the Efficacy (in Terms of Clearance of RhD-positive RBCs) and Safety of LFB-R593, a Monoclonal Anti-RhD Antibody vs a Polyclonal Anti-RhD Immunoglobulin in Healthy RhD Negative Volunteers
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2009
Completion date
July 31, 2011
Enrollment
78 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy